Published in Cell Prolif on January 01, 1993
Cell cycle regulation to repair the infarcted myocardium. Heart Fail Rev (2003) 0.84
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics (Sao Paulo) (2013) 0.78
Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod (2002) 3.59
Microscopic haematuria. BMJ (1994) 3.00
[Cushing's syndrome. I. New diagnostic developments]. Ned Tijdschr Geneeskd (2006) 2.73
Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology (1999) 2.42
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab (2000) 2.36
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology (2001) 2.28
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. Prostate (1995) 2.07
Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab (2011) 2.02
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. J Clin Endocrinol Metab (1992) 1.72
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab (2008) 1.60
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Future prospects in prostate cancer. Prostate (1999) 1.53
Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol (1998) 1.51
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. Hum Reprod (2008) 1.46
Haemodynamic and neurohumoral effects of xenon anaesthesia. A comparison with nitrous oxide. Anaesthesia (1990) 1.44
Relationship between ovarian production of estrone, estradiol, testosterone, and androstenedione and the ovarian degree of stromal hyperplasia in postmenopausal women. Menopause (1998) 1.43
Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF. J Assist Reprod Genet (2005) 1.42
Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) (1997) 1.41
'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatment of chronic hepatitis C patients. J Gastroenterol Hepatol (2001) 1.41
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab (1984) 1.39
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
Corticosteroid therapy in severe illness. N Engl J Med (1997) 1.38
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab (2012) 1.35
Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab (1998) 1.33
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology (2008) 1.31
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
Detection of prostate cancer. BMJ (1995) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
Evaluation of a radioimmunoassay for testosterone estimation. J Steroid Biochem (1973) 1.23
Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online (2008) 1.21
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet (1982) 1.20
Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology (1996) 1.20
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab (2008) 1.18
Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod (2009) 1.17
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer (2010) 1.16
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer (1999) 1.16
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab (1999) 1.16
Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. Hum Reprod (2009) 1.15
Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology (1995) 1.15
A novel tool in the diagnosis and follow-up of (cyclic) Cushing's syndrome: measurement of long-term cortisol in scalp hair. J Clin Endocrinol Metab (2012) 1.14
Thyroid hormone transport by the heterodimeric human system L amino acid transporter. Endocrinology (2001) 1.12
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med (2000) 1.11
Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod (2008) 1.10
Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol (1998) 1.10
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril (1990) 1.07
Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen (1996) 1.06
Hormonal manipulation of prostatic cancer. BMJ (1991) 1.06
11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol (2004) 1.05
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol (2007) 1.05
Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate (1993) 1.05
Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol (1999) 1.04
A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab (1998) 1.04
Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate (1999) 1.04
Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol (1998) 1.04
Effects of extracorporeal shock wave lithotripsy (ESWL) on renal tissue. A review. Urol Res (1989) 1.04
Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther (1987) 1.03
Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol (1995) 1.03
Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab (1992) 1.03
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int (1995) 1.01
Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. Biochem J (1996) 1.01
Plasma oestradiol-17beta and its relationship to serum follicle-stimulating hormone in immature female rats. J Endocrinol (1973) 1.01
Inhibin: 1985 update on action and purification. Mol Cell Endocrinol (1985) 1.01
Effect of gonadotrophins on the secretion of oestradiol- and testosterone by the rat testis. J Endocrinol (1973) 1.01
Screening for prostate cancer. Eur J Cancer (2005) 1.01
Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol (2012) 1.00